BridgeBio Pharma disclosed in a filing with Securities & Exchange Commission the sale of it’s 17,150 shares by its Chairman Frank Mccormick amounting to $6,13,970. With this transaction Frank Mccormick now directly owns 13,35,895 shares valued at approximately $47,825,041.

It’s been observed that a number of large investors have recently either added or reduced their stake in the company. California State Teachers Retirement System acquired a new position in BridgeBio Pharma in third quarter valued at approx. $7,56,000. Times Square Capital Management LLC reduced its stake by 258.9% in the third quarter leaving them with the ownership of 5,38,330 shares valued at $11,558,000.

BridgeBio Pharma is into production and distribution of medicines for genetic disease. Company has 15 development programmes which includes product candidates ranging from early discovery to late-stage development in areas like genetic dermatology, oncology, cardiology, neurology, endocrinology, renal diseases and ophthalmology.